Key result
PET-FDG demonstrated a sensitivity of 95% and specificity of 97% for the diagnosis of adrenocortical carcinoma, and strongly correlated with the Weiss score (77%, P≤0.0001).
Why the study?
Does PET-FDG imaging accurately diagnose adrenocortical carcinoma in patients with adrenal tumors?
Observational (n=51)
No
Does PET-FDG imaging accurately diagnose adrenocortical carcinoma in patients with adrenal tumors?
Effect estimate: Sensitivity 95%, Specificity 97%
Preoperative PET-FDG imaging provides high sensitivity and specificity for diagnosing adrenocortical carcinoma in patients with adrenal tumors, potentially guiding surgical management.
PET-FDG may support ACC diagnosis in adrenal tumors; observational data leaves open need for prospective validation before practice change.
BACKGROUND: Adrenal incidentaloma are frequent in the general population. It can be difficult to diagnose adrenocortical carcinomas among them, even with the progress of imaging techniques. We studied the results of PET-FDG in the diagnosis of such tumours. METHODS: We studied patients referred to the Department of Endocrine Surgery at La Timone Hospital, Marseilles, France, between June 2006 and October 2010 for adrenal tumours. All patients underwent a complete work-up (biological tests and imagery), completed with PET-FDG. We compared the results of PET-FDG and molecular analysis with Weiss score and clinical follow-up. We calculated correlations with the Pearson test. RESULTS: A total of 51 patients were studied. We found that PET-FDG had a sensitivity of 95% and specificity of 97% for the diagnosis of adrenocortical carcinoma. The correlation between PET-FDG and Weiss score was 77% (P ≤ 0.0001). Molecular analyses were correlated as well with Weiss score and malignancy (P < 0.05). CONCLUSIONS: The nature of atypical adrenal masses can be difficult to define during preoperative investigations. For undetermined tumours smaller than 6 cm, characterization with PET-FDG can be one more diagnostic argument pointing to malignancy. It could potentially change the therapeutic strategy and surgical management. In our experience, molecular analyses are available after surgery and have less impact on the therapeutic strategy than PET-FDG. Preoperative PET-FDG can be an asset in the management of adrenal incidentaloma and adrenocortical carcinoma.
No takes yet. Share an insight, caveat, or question.
Gust et al. (2011) conducted an observational in Adrenal tumours (n=51). PET-FDG was evaluated on Diagnosis of adrenocortical carcinoma (Sensitivity 95%, Specificity 97%). PET-FDG demonstrated a sensitivity of 95% and specificity of 97% for the diagnosis of adrenocortical carcinoma, and strongly correlated with the Weiss score (77%, P≤0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: